Concepts (153)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptor, erbB-2 | 6 | 2019 | 133 | 2.240 |
Why?
|
| Breast Neoplasms | 15 | 2019 | 1502 | 2.160 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2019 | 222 | 1.080 |
Why?
|
| Epigenesis, Genetic | 3 | 2019 | 219 | 1.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2019 | 807 | 1.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2014 | 269 | 0.760 |
Why?
|
| S100 Proteins | 1 | 2019 | 12 | 0.680 |
Why?
|
| Neoplasm Proteins | 2 | 2013 | 213 | 0.640 |
Why?
|
| Cell Line, Tumor | 10 | 2019 | 2231 | 0.610 |
Why?
|
| Chromatin | 1 | 2019 | 169 | 0.610 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 197 | 0.520 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 626 | 0.510 |
Why?
|
| Signal Transduction | 4 | 2019 | 1908 | 0.500 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2014 | 30 | 0.470 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 54 | 0.450 |
Why?
|
| Prostatic Neoplasms | 3 | 2022 | 935 | 0.440 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2012 | 12 | 0.430 |
Why?
|
| Neoplasms | 2 | 2022 | 1103 | 0.430 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2014 | 70 | 0.390 |
Why?
|
| Forkhead Transcription Factors | 2 | 2014 | 76 | 0.380 |
Why?
|
| Transcription Factors | 3 | 2015 | 681 | 0.360 |
Why?
|
| Caspase 8 | 1 | 2010 | 32 | 0.360 |
Why?
|
| Serpins | 1 | 2010 | 27 | 0.350 |
Why?
|
| CpG Islands | 1 | 2010 | 97 | 0.350 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 290 | 0.320 |
Why?
|
| Humans | 21 | 2022 | 37093 | 0.320 |
Why?
|
| Amino Acid Transport Systems | 1 | 2006 | 5 | 0.290 |
Why?
|
| Paclitaxel | 1 | 2006 | 50 | 0.280 |
Why?
|
| DNA Methylation | 1 | 2010 | 325 | 0.280 |
Why?
|
| Amino Acids | 1 | 2006 | 145 | 0.270 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2006 | 110 | 0.260 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2019 | 76 | 0.250 |
Why?
|
| beta Catenin | 2 | 2017 | 48 | 0.250 |
Why?
|
| Cell Proliferation | 4 | 2017 | 1198 | 0.250 |
Why?
|
| Estrogen Receptor alpha | 2 | 2015 | 111 | 0.230 |
Why?
|
| Apoptosis | 3 | 2022 | 1398 | 0.220 |
Why?
|
| Female | 13 | 2018 | 20969 | 0.220 |
Why?
|
| Receptors, Calcitriol | 2 | 2014 | 69 | 0.210 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 5 | 0.210 |
Why?
|
| Lymphokines | 1 | 2002 | 13 | 0.210 |
Why?
|
| Enzyme Inhibitors | 3 | 2010 | 433 | 0.200 |
Why?
|
| Antineoplastic Agents | 3 | 2022 | 803 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2017 | 161 | 0.180 |
Why?
|
| Exosomes | 1 | 2022 | 101 | 0.180 |
Why?
|
| Epidermal Growth Factor | 1 | 2019 | 68 | 0.170 |
Why?
|
| Cell Movement | 3 | 2017 | 571 | 0.160 |
Why?
|
| Morpholines | 2 | 2010 | 69 | 0.160 |
Why?
|
| Chromones | 2 | 2010 | 54 | 0.160 |
Why?
|
| Hela Cells | 1 | 2019 | 366 | 0.150 |
Why?
|
| Histones | 1 | 2019 | 190 | 0.150 |
Why?
|
| Chemokine CXCL1 | 1 | 2017 | 15 | 0.150 |
Why?
|
| Thiosemicarbazones | 1 | 2017 | 10 | 0.150 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 24 | 0.150 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 85 | 0.150 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 2014 | 28 | 0.140 |
Why?
|
| Pyrazoles | 1 | 2017 | 85 | 0.140 |
Why?
|
| Models, Biological | 3 | 2022 | 677 | 0.140 |
Why?
|
| RNA, Messenger | 3 | 2013 | 1207 | 0.140 |
Why?
|
| Haplotypes | 2 | 2014 | 182 | 0.130 |
Why?
|
| Cadherins | 2 | 2014 | 90 | 0.130 |
Why?
|
| Gene Expression | 1 | 2018 | 674 | 0.120 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2014 | 3 | 0.120 |
Why?
|
| Animals | 6 | 2022 | 15081 | 0.120 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2014 | 29 | 0.120 |
Why?
|
| Mammary Glands, Animal | 1 | 2014 | 26 | 0.120 |
Why?
|
| Lactation | 1 | 2014 | 40 | 0.120 |
Why?
|
| Drug Synergism | 2 | 2013 | 177 | 0.120 |
Why?
|
| Middle Aged | 5 | 2014 | 10129 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 78 | 0.110 |
Why?
|
| STAT3 Transcription Factor | 1 | 2013 | 90 | 0.110 |
Why?
|
| Los Angeles | 1 | 2013 | 380 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 623 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2018 | 136 | 0.100 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 113 | 0.100 |
Why?
|
| Transcriptional Activation | 1 | 2012 | 172 | 0.100 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 617 | 0.100 |
Why?
|
| Alleles | 1 | 2013 | 321 | 0.100 |
Why?
|
| Mice | 4 | 2015 | 5913 | 0.100 |
Why?
|
| Male | 5 | 2022 | 20025 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 307 | 0.090 |
Why?
|
| Hydroxamic Acids | 1 | 2010 | 32 | 0.090 |
Why?
|
| Phenotype | 1 | 2012 | 689 | 0.090 |
Why?
|
| Enzyme Activation | 1 | 2010 | 444 | 0.080 |
Why?
|
| Transfection | 1 | 2010 | 523 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 1371 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 441 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2010 | 435 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 515 | 0.070 |
Why?
|
| Ethylmaleimide | 1 | 2006 | 9 | 0.070 |
Why?
|
| Starvation | 1 | 2006 | 12 | 0.070 |
Why?
|
| Maleimides | 1 | 2006 | 13 | 0.070 |
Why?
|
| Alanine | 1 | 2006 | 30 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2008 | 325 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 583 | 0.070 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2006 | 133 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2006 | 44 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2006 | 4 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 251 | 0.070 |
Why?
|
| Sodium | 1 | 2006 | 103 | 0.070 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2006 | 26 | 0.070 |
Why?
|
| Caspases | 1 | 2006 | 147 | 0.070 |
Why?
|
| Doxorubicin | 1 | 2006 | 84 | 0.070 |
Why?
|
| Blotting, Northern | 1 | 2006 | 150 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2006 | 269 | 0.070 |
Why?
|
| Flavonoids | 1 | 2006 | 87 | 0.070 |
Why?
|
| Imidazoles | 1 | 2006 | 126 | 0.070 |
Why?
|
| Pyridines | 1 | 2006 | 116 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 893 | 0.060 |
Why?
|
| Adult | 3 | 2013 | 11712 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2017 | 502 | 0.060 |
Why?
|
| Base Sequence | 1 | 2006 | 997 | 0.060 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 409 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 1039 | 0.060 |
Why?
|
| Amino Acid Sequence | 1 | 2006 | 1180 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 578 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 1568 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2018 | 928 | 0.050 |
Why?
|
| Hormones | 1 | 2022 | 55 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 6 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2002 | 37 | 0.050 |
Why?
|
| Menopause | 1 | 2002 | 56 | 0.050 |
Why?
|
| Recurrence | 1 | 2002 | 131 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2022 | 127 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 1015 | 0.050 |
Why?
|
| Ligands | 1 | 2022 | 349 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2014 | 1130 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2002 | 1369 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2018 | 90 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 173 | 0.040 |
Why?
|
| Time Factors | 1 | 2002 | 1742 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 219 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 448 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2022 | 426 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 2014 | 59 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2015 | 65 | 0.030 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2015 | 70 | 0.030 |
Why?
|
| Cyclic S-Oxides | 1 | 2013 | 2 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 337 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2013 | 61 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 67 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 131 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 169 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 448 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 601 | 0.030 |
Why?
|
| Survival Rate | 1 | 2013 | 311 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 182 | 0.030 |
Why?
|
| Genotype | 1 | 2014 | 730 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 859 | 0.020 |
Why?
|
| Vitamin D | 1 | 2013 | 196 | 0.020 |
Why?
|
| Aged | 1 | 2002 | 6741 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 1492 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 767 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2014 | 2026 | 0.020 |
Why?
|